iRhythm Technologies Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" iRhythm Technologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRTC, but not buy additional shares or sell existing shares.
View analyst ratings for iRhythm Technologies or view top-rated stocks.

Wall Street analysts have given iRhythm Technologies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iRhythm Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

iRhythm Technologies saw a increase in short interest in June. As of June 30th, there was short interest totaling 2,210,000 shares, an increase of 22.1% from the June 15th total of 1,810,000 shares. Based on an average daily trading volume, of 781,700 shares, the days-to-cover ratio is presently 2.8 days. Approximately 7.7% of the company's shares are short sold.
View iRhythm Technologies' Short Interest.

iRhythm Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for iRhythm Technologies.

iRhythm Technologies will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

iRhythm Technologies, Inc. (NASDAQ:IRTC) issued its earnings results on Thursday, May, 6th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.87) by $0.08. The company had revenue of $74.31 million for the quarter, compared to analyst estimates of $70.35 million. iRhythm Technologies had a negative net margin of 22.67% and a negative trailing twelve-month return on equity of 22.67%. The company's revenue was up 17.0% on a year-over-year basis. During the same period last year, the firm posted ($0.34) EPS.
View iRhythm Technologies' earnings history.

iRhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IRTC shares have decreased by 39.1% and is now trading at $52.07.
View which stocks have been most impacted by COVID-19.

11 brokers have issued 12 month price objectives for iRhythm Technologies' stock. Their forecasts range from $80.00 to $273.00. On average, they expect iRhythm Technologies' stock price to reach $168.73 in the next twelve months. This suggests a possible upside of 224.0% from the stock's current price.
View analysts' price targets for iRhythm Technologies or view top-rated stocks among Wall Street analysts.

20 employees have rated iRhythm Technologies CEO Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among iRhythm Technologies' employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to iRhythm Technologies include Integra LifeSciences (IART), Nevro (NVRO), Inspire Medical Systems (INSP), Inari Medical (NARI), ICU Medical (ICUI), AtriCure (ATRC), Merit Medical Systems (MMSI), NuVasive (NUVA), Haemonetics (HAE), Axonics (AXNX), Glaukos (GKOS), The Beauty Health (SKIN), Inovio Pharmaceuticals (INO), Luminex (LMNX) and Sight Sciences (SGHT).
View all of IRTC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Teladoc Health (TDOC), The Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and The Boeing (BA).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

iRhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

iRhythm Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.01%). Company insiders that own iRhythm Technologies stock include David A Vort, Kevin M King, Mark J Day, Matthew C Garrett, Ralph Snyderman and Raymond W Scott.
View institutional ownership trends for iRhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold iRhythm Technologies company stock in the last year include David A Vort, Kevin M King, and Mark J Day.
View insider buying and selling activity for iRhythm Technologies or view top insider-selling stocks.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRTC stock can currently be purchased for approximately $52.07.

iRhythm Technologies has a market capitalization of $1.53 billion and generates $265.17 million in revenue each year. The company earns $-43,830,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

iRhythm Technologies employs 1,157 workers across the globe.

The official website for iRhythm Technologies is www.irhythmtech.com.

iRhythm Technologies is headquartered at 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103.

iRhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]